Real Time Search
CES A80 :
CES HKMI :
CES 120 :
Total Turn.

Innovent Announces Retirement of CFO and Appointment of New CFO

2024-02-05 16:45:00

ROCKVILLE, Md. and SUZHOU, China, Feb. 5, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("c") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, announced that Mr. Ronald Hao Xi Ede will retire from his position as the chief financial officer after a seven-year distinguished career with the Company. Mr. Ede will continue to serve on the Board as an executive director, participating in the Board's strategic and business decisions, as well as serve as the managing partner of the Company's funds and take full charge of the Company's fund management.

Mr. Ede joined Innovent in 2017 and, during his CFO tenure, has made significant contributions to the Company's strategy planning, corporate governance, financial management and business development. He successfully led the listing of the Company on the Main Board of the Hong Kong Stock Exchange and a series of post-listing fund raising activities, which have laid a solid foundation for Innovent's continuous growth.

At the same time, Innovent has appointed Ms. Fei You as the new CFO, effective February 5, 2024. She will be responsible for Innovent's financial management and capital market activities. Ms. You has over 20 years of experience in financial management, strategic investment and financing. Before joining Innovent, she served as the chief financial officer of Jinxin Fertility Group Ltd. (HKEx stock code: 1951) and successfully led its listing on the Main Board of the Hong Kong Stock Exchange. Prior to that, she had served in various managerial positions with 3SBio Inc. (HKEx stock code: 1530) and KPMG.

"We are deeply grateful for the dedication and contribution Ronnie has made during his entire tenure at Innovent. His strategic judgment and leadership were instrumental in transforming Innovent from a biotech company to a biopharma enterprise, and leaves us in a solid position to continue pursuing our long-term global vision. We will continue to work with him on the Board of the Company and in other areas, "said Dr. Michael Yu, Founder, Chairman and CEO of Innovent Biologics. "At the same time, we warmly welcome Ms. Fei You as our new CFO. Ms. You has extensive expertise and experience in financial management and capital markets in the healthcare industry. We look forward to working with her on the journey toward pursuing our mission of 'developing high-quality biopharmaceuticals that are affordable to ordinary people' and our vision of "being one of the world's leading biopharmaceutical companies.'"

About Innovent

Inspired by the spirit of "Start with Integrity, Succeed through Action," Innovent's mission is to discover and develop, manufacture and commercialize high-quality biopharmaceutical products that are affordable to ordinary people. Established in 2011, Innovent is committed to discovering and developing, manufacturing and commercializing high-quality innovative medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, and ophthalmology diseases to enhance the quality of the patients' lives. Innovent has 10 products in the market, including TYVYT® (Sintilimab Injection), BYVASDA® (Bevacizumab Injection), SULINNO® (Adalimumab Injection), HALPRYZA® (Rituximab Injection), Pemazyre® (Pemigatinib Oral Inhibitor), olverembatinib, Cyramza® (Ramucirumab Injection), Retsevmo® (Selpercatinib Capsules ), FUCASO® (Equecabtagene  Autoleucel Injection) and SINTBILO® (Tafolecimab Injection). Additionally, it has 2 NDA under NMPA review, 5 assets in Phase III or pivotal clinical trials, and 19 more molecules in early clinical stage.

Innovent has also entered into 30 strategic collaborations with Eli Lilly, Roche, Sanofi, Adimab, Incyte, MD Anderson Cancer Center and other international partners. We strive to work with many collaborators to help advance the biopharmaceutical industry, improve drug availability and enhance the quality of the patients' lives.

Note:

TYVYT® (sintilimab injection) is not an approved product in the United States.

BYVASDA® (bevacizumab biosimilar injection), SULINNO®, and HALPRYZA® (rituximab biosimilar injection) are not approved products in the United States.

TYVYT® (sintilimab injection, Innovent)

BYVASDA® (bevacizumab biosimilar injection, Innovent)

HALPRYZA® (rituximab biosimilar injection, Innovent)

SULINNO® (adalimumab biosimilar injection, Innovent)

Pemazyre® (pemigatinib oral inhibitor, Incyte Corporation). Pemazyre® was discovered by Incyte Corporation and licensed to Innovent for development and commercialization in Mainland China, Hong Kong, Macau and Taiwan.

CYRAMZA® (ramucirumab, Eli Lilly). Cyramza® was discovered by Eli Lilly and licensed to Innovent for commercialization in Mainland China.

Retsevmo® (selpercatinib, Eli Lilly). Retsevmo® was discovered by Eli Lilly and licensed to Innovent for commercialization in Mainland China.

Disclaimer: Innovent does not recommend any off-label usage.

Innovent's Forward-Looking Statements

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions.

Link

PR Newswire News

2024-04-25
13:52:00
Cherrypicks Partners with AWS DevAx Leading Cloud Technology Innovation for Hong Kong Enterprises
11:00:00
Eddid Financial Appointed as Participating Dealer for All Six of the First Batch of Spot Bitcoin and Ether ETFs
10:02:00
Innovent to Present Clinical Data of Multiple Novel Molecules at the 2024 ASCO Annual Meeting
09:02:00
ASCO 2024 | Ascentage Pharma to Present Four Studies, Including an Oral Report Featuring the Latest Data of Olverembatinib in SDH-Deficient GIST
2024-04-24
22:31:00
GenScript Biotech Releases 2023 ESG Report: Deepening Green Development Practices, Constructing Sustainable Future Blueprint
22:00:00
Newborn Town's Q1 Revenue Exceeds RMB 1,000 Million as Social Networking Business Records Over 65% YoY Growth
20:41:00
Tuya Filed 2023 Annual Report on Form 20-F and Released Inaugural Environmental, Social and Governance Report
20:15:00
Asia's Digital Asset Pioneer - Harvest Bitcoin Spot ETF and Harvest Ether Spot ETF Officially Authorized
20:00:00
Roborock S8 MaxV Ultra Breaks New Ground as the First Robotic Vacuum to Achieve Matter Certification
19:43:00
Noah Holdings Limited Files 2023 Annual Report on Form 20-F
19:41:00
Noah Releases 2023 Chairwoman/CEO Letter
18:00:00
iPeakoin Expands Global Presence with New Office in Singapore
17:30:00
Autohome Inc. to Announce First Quarter 2024 Financial Results on May 8, 2024
17:20:00
New Oriental Announces Results for the Third Fiscal Quarter Ended February 29, 2024
17:05:00
Vantage Foundation supports education activities of the UNESCO South Asia Regional Office in New Delhi in India
14:00:00
Digital Edge achieves industry leading sustainability milestones as it publishes third ESG report
10:00:00
Zetrix/MYEG and MaiCapital Ink MoU to Launch Virtual Asset Funds
2024-04-23
21:05:00
Lufax Announces Annual General Meeting on May 30, 2024 and Filing of Its Annual Report on Form 20-F
20:28:00
L'ORÉAL HONG KONG CONCLUDES INAUGURAL COMMUNITY FAIR WITH SUCCESS, FOSTERING COMMITMENT TO DIVERSITY, EQUITY & INCLUSION
19:52:00
Ping An Reports RMB38,709 million of Operating Profit Attributable to Shareholders of the Parent Company in Q1 2024, Life & Health NBV grew 20.7% YoY
Back to Top